Published in Gynecol Oncol on February 01, 1990
Efficacy of Letrozole in Recurrent Ovarian Cancer (MITO32) | NCT04421547
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs (2010) 1.51
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer (2003) 1.11
Treatment for recurrent ovarian cancer-at first relapse. J Oncol (2009) 1.08
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol (2012) 0.99
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer (2003) 0.98
Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol (2010) 0.96
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev (2015) 0.89
Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol (2003) 0.85
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res (2011) 0.85
Taxol: an important new drug in the management of epithelial ovarian cancer. Yale J Biol Med (1992) 0.84
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol (2013) 0.83
A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. Br J Cancer (2005) 0.83
Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer (1995) 0.81
Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles. ACS Appl Mater Interfaces (2013) 0.81
Adoptive immunotherapy against ovarian cancer. J Ovarian Res (2016) 0.79
Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med (2015) 0.78
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer (2003) 0.78
Phase II trial of trimelamol in refractory ovarian cancer. Br J Cancer (1991) 0.78
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Cancer Chemother Pharmacol (2008) 0.78
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer (2011) 0.77
Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel. Biomark Cancer (2016) 0.77
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol (2011) 0.76
Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC Suppl (2015) 0.75
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer (2017) 0.75
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol (2010) 0.75
Clinical features of long-term survivors of recurrent epithelial ovarian cancer. Int J Clin Oncol (2014) 0.75
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Oncologist (2017) 0.75
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) (1976) 5.03
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol (1992) 2.27
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
Chemotherapy of sarcoma. A comparison of three regimens. Lancet (1978) 1.75
Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet (1977) 1.69
Prolymphocytic leukaemia. Br J Haematol (1974) 1.66
Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep (1976) 1.64
Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ (1991) 1.46
Chronic myelomonocytic leukaemia. Br J Haematol (1975) 1.45
Pneumocystis carinii pneumonia following cyclosporine A and methotrexate treated rheumatoid arthritis. J Rheumatol (1992) 1.42
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1983) 1.42
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol (1986) 1.40
Limitations of surgery in the treatment of retroperitoneal sarcoma. Br J Surg (1991) 1.36
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep (1983) 1.32
Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol (1997) 1.29
31P-NMR studies of a human tumour in situ. Lancet (1983) 1.27
A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol (1986) 1.25
The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer (1992) 1.25
Prolymphocytic leukaemia of B and T cell type. Lancet (1973) 1.23
Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol (1981) 1.14
Treatment of extremity soft tissue sarcomas with surgery and radiotherapy. Radiother Oncol (1990) 1.12
Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer (1992) 1.06
Ovarian trials at the Royal Marsden. Cancer Treat Rev (1985) 1.04
How nephrotoxic is carboplatin? Br J Cancer (1990) 1.03
Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol (1993) 1.02
The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol (1989) 1.01
Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer (1989) 1.01
Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res (1989) 1.00
Endometrial stromal sarcomas. Gynecol Oncol (1990) 1.00
Limb function following conservation treatment of adult soft tissue sarcoma. Eur J Cancer (1991) 0.99
Chemotherapy in the management of extramedullary plasmacytoma. Cancer Chemother Pharmacol (1978) 0.99
Is delayed treatment justified in carcinoma of the prostate? Br J Urol (1985) 0.95
Methotrexate in treatment of sarcomata. Br Med J (1967) 0.93
Clinical spectrum of lymphoproliferative diseases. Cancer (1978) 0.93
A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemother Pharmacol (1989) 0.93
Lymphomas of the cervix and upper vagina: a report of five cases and a review of the literature. Gynecol Oncol (1992) 0.92
Metastasizing leiomyoma of the uterus and hormonal manipulations. Case report. Br J Obstet Gynaecol (1986) 0.92
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol (1997) 0.92
Binding of peanut lectin to germinal-centre cells: a marker for B-cell subsets of follicular lymphoma? Br J Cancer (1981) 0.92
The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer (1989) 0.91
Blast crisis of chronic myeloid leukaemia (CML). I. Presentation simulating acute lymphoid leukaemia (ALL). Br J Haematol (1976) 0.91
Pituitary apoplexy following metastasis of bronchogenic adenocarcinoma to a prolactinoma. Clin Endocrinol (Oxf) (1999) 0.91
Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol (1994) 0.90
Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer (1984) 0.90
New approach to immunotherapy of melanoma. Lancet (1971) 0.90
Primary carcinoma of the fallopian tube. Report of 22 cases. Br J Obstet Gynaecol (1981) 0.90
Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol (1991) 0.90
The role of cytoreductive surgery in advanced carcinoma of the ovary: an analysis of primary and second surgery. Br J Obstet Gynaecol (1985) 0.90
Follicular lymphoma: A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukaemia. Br J Cancer Suppl (1975) 0.89
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol (1998) 0.89
Chemotherapy of endodermal sinus tumour (yolk sac tumour) of the ovary: preliminary communication. J R Soc Med (1982) 0.89
Effect of thermal conductance on water economy in the antelope jack rabbit, Lepus alleni. J Cell Physiol (1966) 0.88
Retroconversion of immature teratoma of the ovary: CT appearances. Clin Radiol (1991) 0.88
Spontaneous regression in non-Hodgkin's lymphoma. Cancer (1980) 0.87
Squamous carcinoma arising in dermoid cysts and associated with hypercalcemia: a clinicopathologic study of six cases. Gynecol Oncol (1988) 0.87
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer (1999) 0.87
Cancer-related fatigue--a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl) (2003) 0.86
A near-death experience. Lancet (1983) 0.86
Acute lymphoblastic leukaemia: cyclical chemotherapy with three combinations of four drugs (COAP-POMP-CART regimen). Br Med J (1975) 0.86
A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol (1992) 0.86
Semen cryopreservation for patients surviving malignant disease: implications of proposed legislation. Lancet (1988) 0.85
Impaired regulation of neuronal nitric oxide synthase and heart rate during exercise in mice lacking one nNOS allele. J Physiol (2004) 0.85
Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep (1980) 0.85
JMS, successor to cisplatin in advanced ovarian carcinoma? Lancet (1983) 0.84
Immunological studies in a case of T-cell leukaemia. J Clin Pathol (1974) 0.84
Noradrenergic neuron-specific overexpression of nNOS in cardiac sympathetic nerves decreases neurotransmission. J Mol Cell Cardiol (2006) 0.84
Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment. Gynecol Oncol (1998) 0.82
Reduction of functional N-methyl-D-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. J Neurochem (2001) 0.82
Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinog (1993) 0.82
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol (1988) 0.81
Early clinical experience with bleomycin in the United Kingdom in series of 105 patients. Br Med J (1972) 0.81
Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol (1991) 0.81
Acetabular morphology and resurfacing design. J Biomech (2000) 0.81
Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma. Lancet (1981) 0.81
A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group. Br J Urol (1981) 0.80
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev (1983) 0.80
Multiple myeloma in a pair of monozygotic twins: the first reported case. Br J Haematol (1985) 0.80
Audit can reduce inappropriate requests for cytological examination of cerebrospinal fluid. Cytopathology (2004) 0.80
Letter: Progressive multifocal leucoencephalopathy successfully treated with cytosine arabinoside. Br J Haematol (1976) 0.79
Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol (1982) 0.79
Effect of serum growth factors and phorbol ester on growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinog (1992) 0.79
Steroid hormone profile in postmenopausal women with ovarian cancer. Eur J Cancer (1994) 0.79
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. Br J Cancer (1993) 0.79
Blindness associated with high-dose carboplatin. Lancet (1992) 0.79
Hypersensitivity reactions to cisplatin and carboplatin--a report on six cases. Ann Oncol (1992) 0.79
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. Cancer Chemother Pharmacol (1990) 0.79
Letter: Origin of malignant cells in lymphoma apparently originating in anterior mediastinum. Lancet (1974) 0.79
Can uterine artery Doppler velocimetry predict adverse pregnancy outcome in women with antiphospholipid syndrome? Acta Obstet Gynecol Scand (2001) 0.78